Zacks Small Cap Research on MSN46m
DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP; Debt Conversion Strengthens Balance Sheet…
DWTX READ THE FULL DWTX RESEARCH REPORT Business Update First Patient Dosed in Phase 2b Trial of Halneuron® On March 18, 2025 ...
Targeted Oncology30m
Mirvetuximab Shows Lasting Survival Benefit in Resistant Ovarian Cancer
Toon Van Gorp, MD, PhD, discussed findings from the MIRASOL trial and the potential of mirvetuximab to redefine treatment paradigms in ovarian cancer.
Fierce Pharma56m
Sarepta reports 1 death after patient received DMD gene therapy Elevidys
One patient with Duchenne muscular dystrophy (DMD) has passed away following treatment with Sarepta Therapeutics’ gene therapy Elevidys, the biotech ...